secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0001493152-24-050700
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma enters $291K sponsored research agreement with UCSF for PSMA-B theranostic development
--------------------------------------------------------------------------------

- Sponsored research agreement with UCSF, $291,607 cost, 1-year term, for preclinical PSMA-B ligand development.
- UCSF will develop radiosynthetic methods for [18F]FPA-ACUPA probe and test binding in prostate cancer cell lines and mouse models.
- Shuttle holds exclusive license to PSMA-B IP and has filed a patent application with USPTO.
- PSMA-B ligand is a theranostic candidate for prostate cancer diagnosis and therapy, with market opportunities cited.
- Pluvicto market predicted at $2B; PSMA PET imaging market expected to reach $2.0B by 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224050700/0001493152-24-050700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224050700/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-050700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer